United States
Australia
Brazil
Canada
India
Ireland
Japan
Mexico
New Zealand
Philippines
South Africa
United Kingdom
Conversations in Drug Development
Also in Science
Science
BioSpace
by BioSpace
Today: #114 in Science, Japan on our combined chart.
Share this ranking
Claiming needs an RSS feed. Contact us.
Chart positions today · Germany
Not on the United States charts we track today.
Not on the United Kingdom charts we track today.
Not on the Canada charts we track today.
Not on the Australia charts we track today.
Not on the Germany charts we track today.
Not on the Brazil charts we track today.
Not on the Mexico charts we track today.
Not on the New Zealand charts we track today.
Not on the Ireland charts we track today.
Not on the India charts we track today.
Not on the Philippines charts we track today.
Not on the South Africa charts we track today.
If you like BioSpace, try…
FDA Watch
Similar topics: fda and approvals
Pink Sheet Podcasts
Similar topics: fda and drug
Clinical Pharmacology Podcast with Nathan Teuscher
Also in Science
The Top Line
Also in Science
The BioCentury Show
Also in Science
Ranking history · Germany
No ranking history for this show in Germany over the last 7 days.
Latest episodes
-
Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners
October 21, 2026 · 18 minChina cracks down on some biotechnology ownership transfers—but will the new policy impact licensing deals?; Disc Medicine’s Phase 3 data sweep redeems rejected rare disease therapy, teeing up another FDA run; and the ESMO conference gets…
-
Bonus: Q3 2026 Job Market Update
October 20, 2026 · 16 minBioSpace Vice President Chantal Dresner and Angela Gabriel, content manager, life sciences careers, cover what happened in the biopharma job market during the third quarter. They discuss encouraging signs for those looking for their next…
-
The decisions behind scientific progress
October 15, 2026 · 11 minIn this episode of Denatured, sponsored by Cytiva, Jennifer Smith-Parker speaks to Nicolas Pivet, VP & GM, Manufacturing & Digital Solutions at Cytiva. In this episode, we discuss how biopharma has long invested in more data and…
-
J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback
October 14, 2026 · 20 minJohnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio buy and mixed data in a late-stage pulmonary…
-
Beyond equity: Why venture debt is reshaping European biotech
October 8, 2026 · 23 minIn this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture debt buys time when equity can’t — and how Europe’s funding gaps, tranching…
Show 7 more episodesShow fewer episodes
-
Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
October 7, 2026 · 24 minNew data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this week, including Novartis’ nearly $8…
-
The race for access: How the FAIR Act could reclaim U.S. biotech leadership
October 1, 2026 · 20 minIn this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are losing access to rare disease trials happening abroad and…
-
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
September 30, 2026 · 20 minSummit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its Huntington’s disease gene therapy failed to impress; Kyverna…
-
How radioligand therapy is rewriting cancer care
September 24, 2026 · 16 minIn this episode of Denatured presented by Curium, Jennifer Smith-Parker speaks to Mike Patterson, CEO North America and Professor Sabine Brookman-May, vice president and head of Global Clinical Development. We examine radioligand therapy’s…
-
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
September 23, 2026 · 21 minNovo plans to hit $23B in revenue by 2035, has further reduced its workforce by 4,000 and is boosting manufacturing capacity for its Wegovy pill, but investors are unconvinced it will be enough to turn things around; Viking Therapeutics…
-
When vision fades: Rethinking wet AMD and the durability gap
September 17, 2026 · 22 minIn this episode of Denatured, you’ll hear Philip Jacob Rosenfeld, professor of Ophthalmology at the University of Miami Health System and Bascom Palmer Eye Institute, and Wesley Jackson, chief science officer at Valitor. We talk about the…
-
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
September 16, 2026 · 22 minThe FDA held a public forum on Monday to discuss the future of psychedelic therapeutics, followed by a meeting on Wednesday regarding recommendations for reauthorizing the Prescription Drug User Fee Act the day after launching its…
About the show
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.